09:30 – 09:40
Introduction and Welcome
| Dr. Adolfo de la Fuente MD Anderson Cancer Center Madrid-Hospiten, Spain |
09:30 – 10:45
SESSION 1: Myelofibrosis
| Chairs | Dr. Valentín García-Gutiérrez Hospital Universitario Ramón y Cajal, Madrid, Spain Dr. Breno Moreno de Gusmão Beneficência Portuguesa de São Paulo, São Paulo, Brasil Dr. Gilberto Barranco Hospital General de México, Mexico |
| 09:40 - 10:00 | New Response Criteria Dr. Valentín García-Gutiérrez Hospital Universitario Ramón y Cajal, Madrid, Spain |
| 10:00 - 10:20 | Symptomatic and Anemic Myelofibrosis: Can We Treat Everything with a Single Agent? Dr. Santiago Osorio Hospital General Universitario Gregorio Marañón, Madrid, Spain |
| 10:20 - 10:40 | When and Who Should Get a Transplant? Dr. Anabelle Chinea Hospital Universitario Ramón y Cajal, Madrid, Spain |
| 10:40 - 11:00 | Discussion |
11:00 – 11:30
Coffee break
11:30 – 12:50
SESSION 2: IDH1 Meet the Experts
| Chairs | Dr. Claudia Núñez-Torrón Stock Hospital Universitario Infanta Sofía, Madrid, Spain Dr. Mika Kontro Helsinki University Hospital Comprehensive Cancer Center, Finland Dr. Anne Louise Tølbøll Sørensen Copenhagen University Hospital-Rigshospitalet, Denmark |
| 11:30 - 11:50 | Molecular and Genetic Profiling: Transforming Risk Stratification into Targeted Therapy Dr. Margarida Coucelo Unidade Local de Saúde de Coimbra, Portugal |
| 11:50 - 12:10 | Balancing Promise and Peril: Adverse Events in AML Targeted Treatment Dr. Susana Vives Polo Hospital Germans Trias i Pujol, Barcelona, Spain |
| 12:10 - 12:30 | Agile trial Dr. Adolfo de la Fuente MD Anderson Cancer Center Madrid-Hospiten, Spain |
| 12:30 - 12:50 | Discussion with the Experts: Dr. Gail Roboz New York Presbyterian Hospital, USA Dr. Hartmut Döhner Universitätsklinikum Ulm, Germany |
12:50 – 14:10
SESSION 3: MDS 1
| Chairs | Dr. David Valcárcel Hospital Universitario Vall d'Hebron, Institute of Oncology, Barcelona, Spain Dr. Gilberto Barranco Hospital General de México, Mexico Dr. Luís Pedro Monteiro Unidade Local de Saúde São José, Lisboa, Portugal |
| 12:50 - 13:10 | CHIP/CCUS: Is it time to intervene? Dr. Julia Montoro Hospital Universitario Vall d'Hebron, Barcelona, Spain |
| 13:10 - 13:30 | Re-thinking Low Risk MDS Dr. María Díez Campelo Hospital Universitario de Salamanca, Spain |
| 13:30 - 13:50 | The Challenge of High-Risk MDS Dr. Guillermo García-Manero MD Anderson Cancer Center, Houston, USA |
| 13:50 - 14:10 | Discussion |
14:10 – 15:30
Lunch
14:45 – 15:30
LUNCH SESSION: Moleculin
| Sponsored by Moleculin | L-Annamycin - Non-Cardiotoxic Anthracycline; MIRACLE Pivotal AML Study Dr. Paul Waymack CMO at Moleculin |
15:30 – 17:10
SESSION 4: Diagnosis and MRD
| Chairs | Dr. María José Calasanz Clínica Universidad de Navarra, Pamplona, Spain Dr. Margarida Coucelo Unidade Local de Saúde de Coimbra, Portugal Dr. Alessandro Isidori Ospedale Marche Nord, Pesaro, Italy |
| 15:30 - 15:50 | Genetic Characterization in Myeloid Neoplasms at Diagnosis Dr. María José Calasanz Clínica Universidad de Navarra, Pamplona, Spain |
| 15:50 - 16:10 | Value of Cytometry for MRD Monitoring in AML Dr. Sylvie Freeman University of Birmingham, UK |
| 16:10 - 16:30 | MRD Monitoring in Acute Myeloid Leukemia: The Key Role of Molecular Genomics Dr. Eva Barragán Hospital Universitario y Politécnico La Fe, Valencia, Spain |
| 16:30 - 16:50 | MRD Predictive Value in ALL: Multiparametric Flow Cytometry in Clinical Practice Dr. Alberto Orfao Centro de Investigación del Cáncer (Universidad de Salamanca-CSIC), España |
| 16:50 - 17:10 | Discussion |
17:10 – 17:30
Coffee break
17:30 – 18:30
SESSION 5: ALL
| Chairs | Dr. Carlos Plaza UEES Clinic and SOLCA Guayaquil, Ecuador Dr. Mar Tormo Hospital Clínico Universitario de Valencia, Spain Dr. Ana Alarcón Tomás Hospital Universitario Puerta de Hierro, Madrid, Spain |
| 17:30 - 17:50 | Blinatumomab Finally a Reality Dr. Anna Torrent Hospital Universitario Germans Trias i Pujol, Barcelona, Spain |
| 17:50 - 18:10 | And After What? Immunotherapy in R/R ALL (Excluding CAR-T) Dr. Cristina Papayannidis IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy |
| 18:10 - 18:30 | Discussion |
18:30 – 19:50
SESSION 6: The Long Road to a New Treatment
| Chairs | Dr. Mayte Olave Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain Dr. Luís Pedro Monteiro Unidade Local de Saúde São José, Lisboa, Portugal Dr. Adolfo de la Fuente MD Anderson Cancer Center Madrid-Hospiten, Spain |
| 18:30 - 18:50 | Between Lines and Leukemias: Deciphering Trials Dr. Regina García Hospital Universitario Virgen de la Victoria, Málaga, Spain |
| 18:50 - 19:10 | EMA Regulation of New Drugs Dr. Ricardo Cubedo MD Anderson Cancer Center Madrid-Hospiten, Spain |
| 19:10 - 19:30 | New Molecules in Development for AML Dr. Hartmut Döhner Universitätsklinikum Ulm, Germany |
| 19:30 - 19:50 | Discussion |